Cibus Announces Strategic Realignment to Streamline Operations

Cibus ( (CBUS) ) just unveiled an update.

Cibus, Inc. announced a strategic realignment to streamline operations, focusing on the commercial advancement of its weed management traits in rice and partner-funded sustainable ingredient programs. The company aims to reduce its annual net cash burn to $30 million by 2026 through cost-cutting measures, including rationalizing human capital and non-core facilities. Recent regulatory approvals in the U.S., Ecuador, and India support the company’s gene editing technologies, potentially enhancing its market positioning and facilitating future partnerships. Cibus plans to launch its rice traits commercially in Latin America by 2027-2028, with further expansion planned in the U.S. and Asia.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Spark’s Take on CBUS Stock

According to Spark, TipRanks’ AI Analyst, CBUS is a Neutral.

Cibus’s overall score reflects significant financial challenges, with persistent net losses and negative cash flows weighing heavily. Despite some positive momentum in technical indicators and regulatory achievements, the valuation concerns and cash burn issues remain significant risks.

To see Spark’s full report on CBUS stock, click here.

More about Cibus

Cibus, Inc. is a leading agricultural biotechnology company specializing in the development of plant traits using proprietary gene editing technologies. The company focuses on enhancing farming productivity and sustainability through traits like herbicide tolerance in rice and canola, and resistance to diseases such as white mold in canola.

Average Trading Volume: 160,684

Technical Sentiment Signal: Sell

Current Market Cap: $97.65M

Learn more about CBUS stock on TipRanks’ Stock Analysis page.